Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 221, Issue 6, Pages 934-942Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiz528
Keywords
hookworm; lipopeptide; oral vaccine; Nippostrongylus brasiliensis; Necator americanus
Categories
Funding
- National Health and Medical Research Council (NHMRC), Australia (NHMRC Program) [1132975]
- University of Queensland Research Training Program Scholarship
- Swiss National Science Foundation [P2ZHP3_161693]
- NHMRC [APP1117504]
- Swiss National Science Foundation (SNF) [P2ZHP3_161693] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
Background. The human hookworm, Necator americanus, is a parasite that infects almost half a billion people worldwide. Although treatment is available, vaccination is favorable to combat the spread of this parasite due to its wide distribution and continuous reinfection cycle in endemic communities. Methods. We have designed a lipopeptide oral delivery system using a B-cell epitope derived from the aspartic protease Na-APR-1 from N americanus, attached to a T-helper epitope. Lipopeptides were self-assembled into nanoparticles or entrapped in liposomes that were electrostatically coated with alginate and trimethyl chitosan polymer shields. The adjuvant-free vaccine candidates were orally administered to mice and generated a humoral immune response against both peptide antigen, and the parent protein in the hookworm gut. Results. The vaccine candidates were evaluated in a rodent hookworm challenge model, resulting in up to 98% and 99% decreases in mean intestinal worm and egg burdens in immunized mice, respectively. Conclusions. Lipopeptide survived the gastrointestinal conditions, induced humoral immune responses and drived protection against parasite challenge infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available